MedTrace Logo

First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors

NCT07681882 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-08-10

No results posted yet for this study

Summary

This clinical trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy signals of DS1025a, given as a single agent to participants with advanced, metastatic, or unresectable solid tumors.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Unresectable Solid Tumor

Interventions

DRUG

DS1025a

Administered on Day 1

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-06
Primary Completion
2028-01-21
Completion
2029-01-21

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07681882 on ClinicalTrials.gov